Clinical Infectious Diseases · 2022 · 52 citations · 7 references
Veterinary MedicineInfectious DiseasesPharmacotherapyClinical ImmunologyImmunology Of Infectious DiseasesInfectious Disease PharmacotherapyAcute Respiratory Distress SyndromeVaccine EffectivenessEmergency AuthorizationEmergency Treatment AuthorizationImmunocompromised StatusPreexposure Antimicrobial ProphylaxisPropensity Score AdjustmentSars-cov-2 Antiviral TherapySars-cov-2 InfectionSevere Acute Respiratory Syndrome
BACKGROUND: Tixagevimab and cilgavimab, a combined monoclonal antibody (Evusheld), was granted emergency use authorization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preexposure prophylaxis in individuals with immunocompromising conditions. In this study we used population-based real-world data to evaluate the effectiveness of Evusheld in immunocompromised patients. METHODS: Using the computerized database of the largest healthcare provider in Israel, we identified all adult immunocompromised patients who were eligible to receive Evusheld (150 mg tixagevimab and 150 mg cilgavimab) on 15 February 2022. Patients with a documentation of a prior SARS-CoV-2 infection were excluded. A total of 703 patients who received Evusheld were propensity score matched, using a ratio of 1:4, with 2812 patients who had not received Evusheld (control group). Patients were followed through 30 June 2022 for up to 90 days for the first documentation of SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19)-related hospitalization. RESULTS: Overall, 72 patients in the Evusheld group and 377 patients in the control group had SARS-CoV-2 infection, reflecting an incidence rate of 4.18 and 5.64 per 100 person-months, respectively. The hazard ratios were 0.75 (95% confidence interval [CI]: .58-.96) for SARS-CoV-2 infection and 0.41 (95% CI: .19-.89) for COVID-19-related hospitalization in the Evusheld group compared to the control group. The magnitude of relative risk reduction of each outcome was greater in nonobese patients (P for interaction = .020 and .045, respectively). CONCLUSIONS: This study suggests that Evusheld is effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalization in immunocompromised patients. The effectiveness of this dose appears to be greater in nonobese patients.
7
Victoria Furer, Tali Eviatar, Devy Zisman et al. · Annals of the Rheumatic Diseases · 2021 · 691 citations · Full text
Hugh Montgomery, Richard Hobbs, Francisco Padilla et al. · The Lancet Respiratory Medicine · 2022 · 227 citations · Full text
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +5
Jennifer Kertes, Shirley Shapiro Ben David, Noya Engel-Zohar et al. · Clinical Infectious Diseases · 2022 · 71 citations · Full text